SAN DIEGO, Feb. 25, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present and host investor meetings at the following investor conferences:
|
Event: |
TD Cowen 46th Annual Healthcare Conference |
|||
|
Format: |
Fireside Chat and 1×1 Meetings |
|||
|
Presentation Date: |
Tuesday, March 3, 2026 |
|||
|
Presentation Time: |
8:10am PT / 11:10am ET |
|||
|
Location:
|
Boston, MA
|
|||
|
Event: |
Leerink Partners Global Healthcare Conference |
|||
|
Format: |
Fireside Chat and 1×1 Meetings |
|||
|
Presentation Date: |
Tuesday, March 10, 2026 |
|||
|
Presentation Time: |
10:00am PT / 1:00pm ET |
|||
|
Location:
Event: Format: Presentation Date: Presentation Time: Location: |
Miami, FL
The Citizens Life Sciences Conference Fireside Chat and 1×1 Meetings Wednesday, March 11, 2026 8:20am PT / 11:20am ET Miami, FL |
Live audio webcasts of the presentations will be available in the Investor Relations section of the Company’s website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and the Surf Bio hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The development of the Surf Bio polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.
For more information, visit www.halozyme.com and connect with us on LinkedIn.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-302696455.html
SOURCE Halozyme Therapeutics, Inc.
